Citation | Ye, XY; Chen, SY; Wu, S; Yoon, DS; Wang, H; Hong, Z; O'Connor, SP; Li, J; Li, JJ; Kennedy, LJ; Walker, SJ; Nayeem, A; Sheriff, S; Camac, DM; Ramamurthy, V; Morin, PE; Zebo, R; Taylor, JR; Morgan, NN; Ponticiello, RP; Harrity, T; Apedo, A; Golla, R; Seethala, R; Wang, M; Harper, TW; Sleczka, BG; He, B; Kirby, M; Leahy, DK; Li, J; Hanson, RL; Guo, Z; Li, YX; DiMarco, JD; Scaringe, R; Maxwell, B; Moulin, F; Barrish, JC; Gordon, DA; Robl, JA Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11?-Hydroxysteroid Dehydrogenase Type 1 Inhibitor. J Med Chem60:4932-4948 (2017) [PubMed] Article |
---|
SMILES | Cc1cccc(c1)C1(CC(=O)N2CC(O)C2)C2CC3CC1CC(C2)C3O |TLB:19:18:7.20.21:23,8:7:23:17.18.24,5:7:17.19.18:21.22.23,THB:25:24:7.20.21:23,19:20:23:17.18.24,24:18:7:21.22.23,24:22:7:17.19.18,8:7:17.19.18:21.22.23,5:7:23:17.18.24,(74.67,-38.9,;73.34,-38.12,;71.99,-38.88,;70.67,-38.1,;70.68,-36.56,;72.03,-35.81,;73.35,-36.59,;72.04,-34.27,;70.9,-33.24,;69.43,-33.71,;69.11,-35.22,;68.29,-32.68,;68.21,-31.14,;66.67,-31.22,;65.53,-30.19,;66.75,-32.76,;73.24,-33,;74.57,-33.49,;75.96,-33.14,;74.96,-34.42,;73.54,-33.85,;73.54,-32.27,;74.58,-31.03,;73.23,-31.51,;75.98,-31.61,;77.27,-30.77,)| |